Ovarian Cancer

September 4th 2025

Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).

September 2nd 2025

Ovarian cancer deaths remain uneven across age, geography, and racial and ethnic groups, highlighting the need for targeted interventions.

August 29th 2025

Neoadjuvant chemotherapy followed by interval cytoreductive surgery significantly improves survival rates in patients with advanced ovarian cancer compared with chemotherapy alone.

August 27th 2025

Many patients later diagnosed with high-grade serous cancer had prior surgical or genetic testing opportunities that could have reduced their ovarian cancer risk, underscoring the need to expand opportunistic salpingectomy and preventive strategies.